The Moderna COVID-19 vaccine produces neutralizing antibody titers against the Delta variant, although fewer than against the ancestral strain of the virus, the company announced yesterday.

Based on serum samples collected from eight phase 1 trial participants one week after the second dose of the vaccine, the reduction in neutralizing titers ranged from 2.1-fold for the Delta variant to 8.4-fold for Beta variants of the virus, although all the variants tested remained susceptible to mRNA-1273-elicited serum neutralization, the company said.

“These new data are encouraging and reinforce our belief that the Moderna COVID-19 Vaccine should remain protective against newly detected variants,” said CEO Stéphane Bancel.

 

Related News Articles

Headline
The Centers for Disease Control and Prevention last night endorsed Moderna’s COVID-19 vaccine for children aged 6-17, as its advisory committee…
Headline
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices today unanimously recommended Moderna’s COVID-19 vaccine for…
Blog
A recent article in the Washington Post “COVID bailout rescued some hospitals while enriching others” is wrong. The reality is that all of America’s hospitals…
Headline
More than 1 million prescriptions for the COVID-19 antiviral pills Lagevrio and Paxlovid were dispensed between late December 2021 and May 2022, but dispensing…
Headline
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices on Saturday recommended the Moderna vaccine for children aged 6…
Headline
The Food and Drug Administration today authorized Moderna’s COVID-19 vaccine for children aged 6 months through 17 years old and Pfizer’s COVID-19 vaccine for…